APA

van Veggel B., de Langen A. J., Hashemi S., Monkhorst K., Rosenberg E. H., Heideman D. A. M., Radonic T. & Smit E. F. (20190912). Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses. : Lung cancer (Amsterdam, Netherlands).

Chicago

van Veggel Bianca, de Langen Adrianus J, Hashemi Sayed, Monkhorst Kim, Rosenberg Efraim H, Heideman Daniëlle A M, Radonic Teodora and Smit Egbert F. 20190912. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses. : Lung cancer (Amsterdam, Netherlands).

Harvard

van Veggel B., de Langen A. J., Hashemi S., Monkhorst K., Rosenberg E. H., Heideman D. A. M., Radonic T. and Smit E. F. (20190912). Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses. : Lung cancer (Amsterdam, Netherlands).

MLA

van Veggel Bianca, de Langen Adrianus J, Hashemi Sayed, Monkhorst Kim, Rosenberg Efraim H, Heideman Daniëlle A M, Radonic Teodora and Smit Egbert F. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses. : Lung cancer (Amsterdam, Netherlands). 20190912.